Oncolytic viruses-immunotherapeutics on the rise (Q38919107)

7 September 2017

1 reference

title

Oncolytic viruses-immunotherapeutics on the rise (English)

1 reference

7 September 2017

1 reference

1 reference

2

John C Bell

1 reference

7 September 2017

Brian A Keller

1

1 reference

7 September 2017

publication date

4 August 2016

1 reference

Journal of Molecular Medicine

7 September 2017

published in

1 reference

7 September 2017

volume

94

1 reference

7 September 2017

issue

9

1 reference

7 September 2017

page(s)

979-991

1 reference

Breakthrough of the year 2013. Cancer immunotherapy

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Going viral with cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Regulation of type I interferon responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Oncolytic Viruses: Exploiting Cancer's Deal with the Devil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

The tumor suppressor PTEN has a critical role in antiviral innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Stem cell collection and gene transfer in Fanconi anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Treatment of human cancer with mumps virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Tumor-specific promoter-driven adenoviral therapy for insulinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Systemic armed oncolytic and immunologic therapy for cancer with JX-863, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

The oncolytic poxvirus JX-863 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Maraba virus as a potent oncolytic vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

CD40 ligand exhibits a direct antiviral effect on Herpes Simplex Virus type-1 infection via a PI3K-dependent, autophagy-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Use of a targeted oncolytic poxvirus, JX-863, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Management of toxicities of immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Development of PROSTVAC immunotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00109-016-1453-9

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

21 January 2018

1 reference

12 December 2020

Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter

1 reference

12 December 2020

IDO inhibitors move center stage in immuno-oncology

1 reference

12 December 2020

In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.

1 reference

12 December 2020

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

1 reference

12 December 2020

The destructive effects of viruses on transplantable mouse tumors

1 reference

12 December 2020

Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report

1 reference

12 December 2020

History of oncolytic viruses: genesis to genetic engineering

1 reference

12 December 2020

Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus

1 reference

12 December 2020

The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34

1 reference

12 December 2020

Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer

1 reference

12 December 2020

Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression.

1 reference

12 December 2020

10.1007/S00109-016-1453-9

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1031433147

0 references

1 reference